FDA Center for Drug Evaluation & Research Issues Warning Letter to Guangdong Bisutang Biotechnology
November 04, 2026
November 04, 2026
WASHINGTON, Nov. 4 (TNSdock) -- The U.S. Department of Health and Human Services Food and Drug Administration issued the following warning letter to Guangdong Bisutang Biotechnology Co. Ltd. from its Center for Drug Evaluation and Research:
* * *
Recipient: Mr. Jianfang Chen, CEO, Guangdong Bisutang Biotechnology Co., Ltd., Floor 1-5, One of No. 15 (Factory Building 1-1), Industrial Cluster Development Zone, Xiamao Town, Zhaoqing 526243, China
Issuing Offic . . .
* * *
Recipient: Mr. Jianfang Chen, CEO, Guangdong Bisutang Biotechnology Co., Ltd., Floor 1-5, One of No. 15 (Factory Building 1-1), Industrial Cluster Development Zone, Xiamao Town, Zhaoqing 526243, China
Issuing Offic . . .